MTOR and neoplasm: Mutations in the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of the rapamycin (mTOR) pathway are common in BC (20–40%) and are critical causes of aggressive tumor behavior and therapy resistance.